Marcello Damiani
Director/Board Member at Cellarity Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Shannon Klinger | M | 53 |
ModernaTX, Inc.
 ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | 3 years |
| Francois Nader | M | 67 | 5 years | |
| Elizabeth Nabel | M | 72 | 9 years | |
| Stéphane Bancel | M | 51 |
ModernaTX, Inc.
ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | 5 years |
| Stephen Berenson | M | 63 |
Cellarity Inc.
 Cellarity Inc. BiotechnologyHealth Technology Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA. | 7 years |
| Sylvain Morgeau | M | 44 | 13 years | |
| Peter Hutt | M | 89 |
ModernaTX, Inc.
ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | 12 years |
| Lorence Kim | M | 49 |
ModernaTX, Inc.
ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | 10 years |
| Sandra Horning | M | 75 |
Cellarity Inc.
Cellarity Inc. BiotechnologyHealth Technology Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA. | 4 years |
| Avak Kahvejian | M | 48 |
Cellarity Inc.
Cellarity Inc. BiotechnologyHealth Technology Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA. | 7 years |
| Fabrice Chouraqui | M | - |
Cellarity Inc.
Cellarity Inc. BiotechnologyHealth Technology Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA. | 4 years |
| Marie-Hélène Habert-Dassault | F | 59 | 12 years | |
| Stephen Hoge | M | 48 |
ModernaTX, Inc.
ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | - |
| Elizabeth Tallett | F | 74 | 4 years | |
| Paul Sagan | M | 65 | 6 years | |
| Harold Y. H. Boël | M | 59 | 12 years | |
| James Collins | M | 58 |
Cellarity Inc.
Cellarity Inc. BiotechnologyHealth Technology Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA. | 7 years |
| Noubar Afeyan | M | 60 |
Cellarity Inc.
Cellarity Inc. BiotechnologyHealth Technology Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA. | 7 years |
| Saqib Islam | M | 54 |
ModernaTX, Inc.
ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | 8 years |
| Tracey Franklin | F | 44 | 5 years | |
| Jacqueline Miller | M | - | 4 years | |
| Charbel Haber | M | - | 4 years | |
| José M. Vega | M | - | 3 years | |
| Milind Kamkolkar | M | - |
Cellarity Inc.
Cellarity Inc. BiotechnologyHealth Technology Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA. | - |
| Jack Szostak | M | - |
ModernaTX, Inc.
ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | - |
| Melanie Ivarsson | M | - | 4 years | |
| John Lepore | M | - | 4 years | |
| Gregory Moore | M | 59 |
Cellarity Inc.
Cellarity Inc. BiotechnologyHealth Technology Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA. | 1 years |
| Carl Decicco | M | 62 |
Cellarity Inc.
Cellarity Inc. BiotechnologyHealth Technology Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA. | - |
| Patrick Norman Bergstedt | M | - | 4 years | |
| Ian Estepan | M | 48 |
Cellarity Inc.
Cellarity Inc. BiotechnologyHealth Technology Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA. | 3 years |
| Catherine Isted | F | - | 1 years | |
| Kate Cronin | F | 58 | 3 years | |
| Lavina A. Talukdar | F | - | 5 years | |
| Christina Busmalis | F | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Philippe Gillet | M | 66 | - | |
| Olivier Brandicourt | M | 68 | 2 years | |
| Michel Angé | M | 84 | - | |
| Israel Ruiz | M | 52 | - | |
| Agnès Lemarchand | F | 69 | 9 years | |
| Jim Kasinger | M | 52 | 3 years | |
| Joanna Shields | F | 62 | 5 years | |
| Claire Giraut | F | 67 | 5 years | |
| Moncef Slaoui | M | 64 | 3 years | |
| Juan Andres | M | 59 | 6 years | |
| Gentiane Gorlier | M | - | 7 years | |
| Susan Liautaud | M | - | 2 years | |
| Lori M. Henderson | F | 62 | 3 years | |
| Henri Thomasson | M | - | 28 years | |
| Cristina Rondinone | M | 64 |
Cellarity Inc.
Cellarity Inc. BiotechnologyHealth Technology Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA. | 1 years |
| Poorya Hosseini | M | - |
Cellarity Inc.
Cellarity Inc. BiotechnologyHealth Technology Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA. | 4 years |
| Jennifer Ling Lee | F | 61 | - | |
| Tal Zaks | M | 58 | 6 years | |
| Corinne Le Goff | M | 58 | 1 years | |
| Georges Hibon | M | 86 | 10 years | |
| Jason Glashow | M | - | - | |
| Richard J. Wanstall | M | 55 | 4 years | |
| Colleen Hussey | F | - | - | |
| Giuseppe Ciaramella | M | 55 | 4 years | |
| Francine Gregoire | M | 63 | 3 years | |
| Matthew Stanton | M | 51 | 3 years | |
| Sandrine Flory | F | - | 6 years | |
| Lee Cooper | M | - | 2 years | |
| Michael Mullette | M | - | 2 years | |
| Rajin Kang | F | - | 3 years | |
| Daniel Neil | M | - | 7 years | |
| Barry Ticho | M | 64 | 1 years | |
| Wendy S. Arnold | F | 52 | 3 years | |
| Paul Burton | M | 55 | 2 years | |
| Christian Brechot | M | 71 | 4 years | |
| Eileen C. Pruette | F | 65 | 2 years | |
| Anne Drapeau | F | 57 | 3 years | |
| Manuel Méndez Muñiz | M | 56 | 4 years | |
| Megan E. Pace | F | 51 | 2 years | |
| James P. Whelan | M | - | - | |
| Theodore Ashburn | M | 57 | 1 years | |
| Philippe Cleuziat | M | - | - | |
| David Meline | M | 66 | 2 years | |
| Jean-Fabien Monin | M | 54 | 3 years | |
| Mark Miller | M | - | 12 years | |
| Ann Hunter | M | 68 | 7 years | |
| Eric Bouvier | M | 63 | 9 years | |
| Stephen Harbin | M | 66 | - | |
| Mojgan Lefebvre | F | 58 | 3 years | |
| Raymond C. Jordan | M | 70 | - | |
| Theo Melas-Kyriazi | M | 64 | 2 years | |
| Nicholas Keher | M | 42 | 1 years | |
| Robert Dolski | M | 54 | 3 years | |
| Stephanie Engels | F | - | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 60 | 67.42% |
| France | 21 | 23.60% |
| Luxembourg | 10 | 11.24% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Marcello Damiani
- Personal Network
